159 related articles for article (PubMed ID: 21183581)
1. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
Penel N; Van Glabbeke M; Marreaud S; Ouali M; Blay JY; Hohenberger P
Ann Oncol; 2011 Jun; 22(6):1266-1272. PubMed ID: 21183581
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Italiano A; Toulmonde M; Bui-Nguyen B
Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
Ducoulombier A; Cousin S; Kotecki N; Penel N
Crit Rev Oncol Hematol; 2016 Feb; 98():73-80. PubMed ID: 26555460
[TBL] [Abstract][Full Text] [Related]
4. Systemic management strategies for metastatic soft tissue sarcoma.
Movva S; Verschraegen C
Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in adult soft tissue sarcoma.
Jain A; Sajeevan KV; Babu KG; Lakshmaiah KC
Indian J Cancer; 2009; 46(4):274-87. PubMed ID: 19749457
[TBL] [Abstract][Full Text] [Related]
7. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
8. Histology-driven chemotherapy of soft-tissue sarcoma.
Eriksson M
Ann Oncol; 2010 Oct; 21 Suppl 7():vii270-6. PubMed ID: 20943627
[TBL] [Abstract][Full Text] [Related]
9. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
10. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.
Casali PG
Ann Oncol; 2012 Sep; 23 Suppl 10():x167-9. PubMed ID: 22987955
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Gutierrez-Sainz L; Martinez-Fdez S; Pedregosa-Barbas J; Peña J; Alameda M; Viñal D; Villamayor J; Martinez-Recio S; Perez-Wert P; Pertejo-Fernandez A; Gallego A; Martinez-Marin V; Zamora P; Espinosa E; Mendiola M; Feliu J; Redondo A
Clin Transl Oncol; 2023 Dec; 25(12):3519-3526. PubMed ID: 37329429
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
Cancer Treat Rev; 2008 Jun; 34(4):339-47. PubMed ID: 18313854
[TBL] [Abstract][Full Text] [Related]
13. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
Demetri GD; Elias AD
Hematol Oncol Clin North Am; 1995 Aug; 9(4):765-85. PubMed ID: 7490240
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of advanced sarcomas of bone and soft tissue.
Antman KH
Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
[TBL] [Abstract][Full Text] [Related]
16. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of advanced soft-tissue sarcomas.
Antman KH; Elias AD
Semin Surg Oncol; 1988; 4(1):53-8. PubMed ID: 3281212
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
19. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
van Oosterom AT; Mouridsen HT; Nielsen OS; Dombernowsky P; Krzemieniecki K; Judson I; Svancarova L; Spooner D; Hermans C; Van Glabbeke M; Verweij J;
Eur J Cancer; 2002 Dec; 38(18):2397-406. PubMed ID: 12460784
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Van Glabbeke M; van Oosterom AT; Oosterhuis JW; Mouridsen H; Crowther D; Somers R; Verweij J; Santoro A; Buesa J; Tursz T
J Clin Oncol; 1999 Jan; 17(1):150-7. PubMed ID: 10458228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
